Clinical trials: Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Repeated-dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, and efficacy of a multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
- Trial name
- NCT06055374
- Testing
- BxC-I17e
- Sponsor
- Brexogen Inc.
Atopic Dermatitis (AD)
A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of…
- Trial name
- MG-K10 (NCT07103174)
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Dermatitis, Atopic
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD
- Trial name
- NCT00673725
- Testing
- Locobase® REPAIR
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Astellas Pharma Europe B.V.
Atopic Dermatitis
Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
This is a randomized open label study to evaluate the long term safety of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT03654755
- Testing
- ASN002
- Where
- 38 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Asana BioSciences
Atopic Dermatitis
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT05579925
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis, Eczema
A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the impact of lebrikizumab treatment on the overall well-being of adult participants with moderate-to-severe AD in real-world clinical practice settings across Europe, as measured…
- Trial name
- ADTrust (NCT06815380)
- Testing
- No Intervention
- Where
- Denmark
- Volunteers
- 1,000 people
- Sponsor
- Almirall, S.A.
Eczema
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema.
- Trial name
- NCT06807268
- Testing
- Abrocitinib
- Where
- 47 sites in United States, China and 6 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Atopic Dermatitis, Plaque Psoriasis
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you…
- Trial name
- NCT05375955
- Testing
- PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Dermatitis, Atopic
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
The primary objective of the study was to evaluate the efficacy and safety of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05544591
- Testing
- 611 Q2W, 611 Q4W
- Where
- 5 sites in China
- Volunteers
- 93 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis
B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis.
- Trial name
- JADE Mono-1 (NCT03349060)
- Testing
- PF-04965842 100 mg, PF-04965842 200 mg
- Where
- 88 sites in United States, Australia and 6 more
- Volunteers
- 387 people
- Sponsor
- Pfizer
Atopic Dermatitis, Eczema
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
The main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADhope (NCT05990725)
- Testing
- Lebrikizumab
- Where
- 33 sites in Germany, Netherlands and 1 more
- Volunteers
- 260 people
- Sponsor
- Almirall, S.A.
Atopic Dermatitis
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
- Trial name
- PossibILity (NCT07277660)
- Testing
- Galvokimig
- Where
- 59 sites in United States, Bulgaria and 7 more
- Volunteers
- 165 people
- Sponsor
- UCB Biopharma SRL
Atopic Dermatitis
Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.
Observational Study to Assess the Safety and Efficacy of FURESTEM-AD lnj. In moderate to Atopic Dermatitis
- Trial name
- NCT03458624
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate…
- Trial name
- NCT05859724
- Testing
- NM26-2198
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Yellow Jersey Therapeutics AG
Atopic Dermatitis
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study was to assess the safety of Dupilumab administered concomitantly with topical corticosteroids (TCS) in patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01639040
- Testing
- Dupilumab, Topical Corticosteroid (TCS)
- Where
- 13 sites in Germany, Hungary and 1 more
- Volunteers
- 31 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis
Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4
The purpose of this trial is to investigate if tralokinumab changes the metabolism of selected CYP substrates in adults with moderate-to-severe AD after: 14 weeks of treatment with tralokinumab a single dose of tralokinumab
- Trial name
- NCT03556592
- Testing
- Tralokinumab, Caffeine, Warfarin
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
The primary objective of the study is to evaluate the pharmacokinetics (PK) of multiple cytochrome P450 (CYP450) substrates alone and in combination with rocatinlimab in participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT05891119
- Testing
- Caffeine, Metoprolol, Midazolam
- Where
- 7 sites in United States
- Volunteers
- 21 people
- Sponsor
- Amgen
Atopic Dermatitis
Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
A Phase I/IIa Clinical Trial to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis
- Trial name
- NCT04725136
- Testing
- FURESTEM-AD inj
- Where
- 2 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- Kang Stem Biotech Co., Ltd.